

SUPPLEMENTARY FIGURE




Figure S1. HDAC4 overexpression is associated with poor prognosis for patients with ESCC independent of clinical stage. (A) The overall survival (OS) and progression-free survival (PFS) of stage I-II ESCC patients with high or low HDAC4 expression. **(B)** OS and PFS of stage III ESCC patients with high or low HDAC4 expression.